FDA lifts clinical hold on AstraZeneca cancer drug studies
The Food and Drug Administration has lifted a partial clinical hold it placed last month on the enrollment of new patients in a late-stage studies AstraZeneca was conducting on new treatments for head and neck cancer.
The clinical trials were for durvalumab as a monotherapy and in combination with tremelimumab, an experimental immuno-oncology drug also in AstraZeneca’s pipeline, for treating head and neck squamous cell carcinoma.
The FDA placed a partial clinical hold on the trials in late October…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news
More News: AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Food and Drug Administration (FDA) | Head and Neck Cancer | Health Management | HNSCC | Pharmaceuticals | Skin Cancer | Squamous Cell Carcinoma | Study